Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology

Rhea-AI Summary

Onco-Innovations (ONNVF) has appointed Professor Steven Jones as Senior Scientific Advisor to strengthen its AI-powered precision oncology initiatives. Jones, currently serving as Co-Director of the Genome Sciences Centre and Head of Bioinformatics at BC Cancer Research Institute, is a distinguished researcher in genomics and cancer research. As Senior Scientific Advisor, he will provide scientific leadership for Onco's oncology genomics and AI initiatives, particularly focusing on the company's flagship AI platform SynoGraph through its subsidiary Inka Health. His responsibilities include guiding scientific direction, fostering research partnerships, supporting fundraising efforts, and representing the company in scientific communities. Jones brings significant expertise as a Fellow of the Royal Society of Canada and is consistently recognized as one of the world's most highly cited researchers by Clarivate Analytics.

Positive

• Appointment of highly credentialed expert in genomics and cancer research strengthens company's scientific leadership
• Addition of world-renowned researcher could enhance credibility with partners and investors
• Strategic alignment with company's AI and precision oncology focus through experienced advisor

Negative

• None.

VANCOUVER, BC / ACCESS Newswire / May 22, 2025 / Onco-Innovations Limited (CBOE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Professor Steven Jones as Senior Scientific Advisor. Professor Jones will play a key role in advancing the Company's mission to transform cancer care through AI-powered precision oncology.

Professor Jones currently serves as Co-Director of the Genome Sciences Centre in Vancouver and Head of Bioinformatics, as well as Distinguished Scientist at the BC Cancer Research Institute. He is internationally recognized as one of the most highly cited researchers in his field, with groundbreaking contributions to genomics and cancer research. Among his many honors, Professor Jones is a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences, and has received multiple awards for leadership in genomics and precision oncology. He is consistently recognized by Clarivate Analytics as one of the world's most highly cited researchers.^[1]

As a world-renowned expert in genomics, bioinformatics, and cancer research, Professor Jones brings decades of precision oncology of experience to Onco-Innovations. A significant part of his prolific research program relates to developing more precise cancer treatments by exploiting the specific genetic profile of an individual's cancer. In his new role, he will provide scientific leadership across the Company's oncology genomics and AI initiatives, working primarily with its subsidiary, Inka Health. Inka Health is the developer of SynoGraph, Onco-Innovations' flagship AI-powered oncology platform, and Professor Jones will help guide its scientific direction. He will also help shape research strategy, support strategic partnerships, and represent the Company within the scientific and medical communities.

Professor Jones' responsibilities will include guiding the scientific direction of Onco's AI-driven solutions, fostering collaborations with research institutions and industry partners, and contributing to key publications and conferences. He will also play an active role in fundraising and public engagement, helping to articulate the scientific value and impact of Onco-Innovations' technologies to investors and other stakeholders.

"Professor Jones is a pioneer in cancer genomics and bioinformatics, and we are honoured to welcome him to Onco-Innovations. His deep expertise and visionary leadership will be instrumental as we expand our precision oncology efforts and deepen our work with data partners, clinicians, and researchers worldwide," said Thomas O'Shaughnessy, CEO of Onco-Innovations.

About Inka Health
Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.

About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

^[1] https://www.bcgsc.ca/people/steven-jones

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

Who is Professor Steven Jones and what is his new role at Onco-Innovations (ONNVF)?

Professor Steven Jones is a renowned expert in genomics and cancer research who has been appointed as Senior Scientific Advisor at Onco-Innovations. He currently serves as Co-Director of the Genome Sciences Centre and Head of Bioinformatics at BC Cancer Research Institute.

What will be Professor Jones' main responsibilities at Onco-Innovations (ONNVF)?

Professor Jones will provide scientific leadership for oncology genomics and AI initiatives, guide the development of the SynoGraph platform, foster research partnerships, support fundraising efforts, and represent the company in scientific communities.

What is SynoGraph and how will Professor Jones contribute to its development?

SynoGraph is Onco-Innovations' flagship AI-powered oncology platform, developed by subsidiary Inka Health. Professor Jones will help guide its scientific direction and development through his expertise in genomics and bioinformatics.

What are Professor Jones' credentials and achievements in the field?

Professor Jones is a Fellow of the Royal Society of Canada and Canadian Academy of Health Sciences, consistently recognized as one of the world's most highly cited researchers by Clarivate Analytics, with significant contributions to genomics and cancer research.